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ABSTRACT The diagnosis of primary ciliary dyskinesia is often confirmed with standard, albeit complex
and expensive, tests. In many cases, however, the diagnosis remains difficult despite the array of
sophisticated diagnostic tests. There is no “gold standard” reference test. Hence, a Task Force supported by
the European Respiratory Society has developed this guideline to provide evidence-based
recommendations on diagnostic testing, especially in light of new developments in such tests, and the need
for robust diagnoses of patients who might enter randomised controlled trials of treatments. The guideline
is based on pre-defined questions relevant for clinical care, a systematic review of the literature, and
assessment of the evidence using the GRADE (Grading of Recommendations, Assessment, Development
and Evaluation) approach. It focuses on clinical presentation, nasal nitric oxide, analysis of ciliary beat
frequency and pattern by high-speed video-microscopy analysis, transmission electron microscopy,
genotyping and immunofluorescence. It then used a modified Delphi survey to develop an algorithm for
the use of diagnostic tests to definitively confirm and exclude the diagnosis of primary ciliary dyskinesia;
and to provide advice when the diagnosis was not conclusive. Finally, this guideline proposes a set of
quality criteria for future research on the validity of diagnostic methods for primary ciliary dyskinesia.
This article has supplementary material available from erj.ersjournals.com
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The guidelines published by the European Respiratory Society (ERS) incorporate data obtained from a comprehensive
and systematic literature review of the most recent studies available at the time. Health professionals are encouraged to
take the guidelines into account in their clinical practice. However, the recommendations issued by this guideline may
not be appropriate for use in all situations. It is the individual responsibility of health professionals to consult other
sources of relevant information, to make appropriate and accurate decisions in consideration of each patient’s health
condition and in consultation with that patient and the patient’s caregiver where appropriate and/or necessary, and to
verify rules and regulations applicable to drugs and devices at the time of prescription.
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Introduction
Primary ciliary dyskinesia (PCD) represents a clinical and genetic heterogeneous group of respiratory
ciliopathies, with reduced mucociliary clearance of the airways. The various mutations result in different
clinical and pathological patterns, contributing to the challenges of diagnosis. There is no single gold
standard diagnostic test for PCD [1]. Current diagnosis requires a combination of technically demanding
investigations, including nasal nitric oxide (nNO), high-speed video microscopy analysis (HSVA) and
transmission electron microscopy (TEM). Historically, clinicians used the saccharine test to screen for
PCD, but this is no longer advocated [2]. Furthermore, more sophisticated diagnostic tests that might
improve diagnostic accuracy (genotyping, immunofluorescence of ciliary proteins and electron microscopy
tomography) are becoming increasingly available.
The availability of tests varies across Europe [3]. This has partially improved recently in response to
collaborations including a former Task Force (2006–2009) of the European Respiratory Society (ERS) [2–4]
and Framework Programme (FP)-7 funded BESTCILIA. The ERS Task Force published a consensus
statement in 2009 [2] to guide diagnostic testing and BESTCILIA has recently introduced diagnostic testing
into three countries where services did not previously exist. Since the 2009 statement, a number of groups
and consortia have investigated the accuracy of various diagnostic tests for PCD, providing the opportunity
to advance the state of diagnostics by developing evidence-based guidelines. Therefore, in 2014 a new PCD
ERS Task Force consisting of adult and paediatric physicians from pulmonology and ear, nose and throat
disciplines along with diagnostic scientists was established. It aimed to develop evidence-based guidelines
for the diagnosis of PCD. This is important for the appropriate clinical management and prognosis of
individual patients with suspected or eventually confirmed PCD to ensure patients with PCD are correctly
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diagnosed, whilst avoiding the problems of false-positive diagnoses. It should also ensure a definitive
diagnosis before PCD patients are enrolled in randomised controlled clinical trials of treatment.
Methods
The methods are described in detail in the supplementary material.
Task Force composition
In brief, the panel consisted of a multidisciplinary group of clinicians and scientists with recognised expertise
in the diagnosis of PCD; junior members/trainees affiliated to European PCD centres were active members
of the committee (table S1). Methodologists from the ERS provided expertise in guideline development
following the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach
for diagnostic tests [5]. Panel members disclosed potential conflicts of interest according to ERS policies at
the start of the Task Force and prior to publication of this manuscript.
Patient-important outcomes
The GRADE approach emphasises the importance of recommendations based on the impact on
patient-important outcomes [6]. The patient representatives to the Task Force fully endorsed that an accurate
diagnosis was an important outcome, because it leads to a better recognition of their problems by physicians
and more effective treatment, and thus improves their health and quality of life. This was confirmed by our
questionnaire survey of 352 PCD patients from 25 countries and 20 in-depth interviews [7]. However,
diagnostic accuracy studies do not provide direct evidence for the improvement of patient-important
outcomes; consequently, the confidence in results of test accuracy studies can be judged, at best, as moderate.
Formulation of the topics and questions
The Task Force members agreed that six facets of PCD diagnostics should be evaluated: clinical symptoms,
nNO, HSVA, TEM, genotype and immunofluorescence labelling of ciliary proteins. We evaluated each test to
see whether it should be included in the diagnostic pathway for PCD, using a “PICO” structured question:
“Patients suspected of having PCD, Investigated by [nNO, TEM, etc.], when Comparing patients with a final
positive or negative diagnostic outcome, what was the diagnostic accuracy (Outcome) of the test?” The PICO
questions for each test were finalised during several rounds of teleconferences and email discussions (table S2).
The essential inclusion criterion for studies was that they must have included consecutive patients referred
for PCD testing in whom the PCD diagnosis was then either confirmed or excluded. We excluded studies if
patients had already had previous diagnostic testing. In the absence of such studies, in the narrative review
we discussed case–control studies that compared PCD patients with healthy controls or patients suffering
from other respiratory diseases (e.g. cystic fibrosis). Results from such studies cannot be generalised to the
clinical situation, where patients with PCD must be distinguished from patients referred for similar
complaints, but without PCD. Thus, the results from case–control studies are far less relevant for clinical
care. The main limitation for this project was the lack of a gold standard diagnostic test for PCD. In the
absence of this, we compared the diagnostic performance indicators (e.g. sensitivity and specificity) to the
authors’ final decision regarding positive/negative PCD diagnosis based on all available tests.
The Task Force also agreed on a list of less structured questions relevant to PCD diagnostics for the
narrative discussion. As the evidence for these questions were not formally graded they were not used for
recommendations.
Literature search methods
We searched Medline and Embase databases (accessed through Ovid) from January 1, 1996 to March 14,
2016. Full details are provided in the supplementary material. In brief, titles and abstracts were screened;
the full text was then reviewed for papers that potentially fulfilled criteria for inclusion. These manuscripts
were checked for completeness by the Task Force panel to ensure all data fulfilling the a priori inclusion
criteria were present. PRISMA flow diagrams show the search process for each Working Group (figure S1).
Quality of evidence and strength of recommendations
We used the GRADE approach through the entire process, from grading the quality of evidence, to
deciding on the strength of the recommendations [8, 9]. Details are provided in the supplementary
material, and include reasons for downgrading the confidence in the evidence (summary of evidence
tables). Recommendations were made based on the strength of evidence and other factors, such as overall
accuracy of the test (sensitivity and specificity), confidence in the net accuracy (range of sensitivity/
sensitivity from included studies and/or confidence intervals of net sensitivity and specificity), and
considerations such as patient acceptability of the test, feasibility of testing and accessibility of the test.
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The four tests, where evidence-based recommendations were made, were all acceptable to the patient,
feasible and acceptable.
Consensus statement for confirming or excluding PCD
We used a modified Delphi survey to reach a consensus regarding the use of diagnostic tests to definitively
confirm and exclude the diagnosis of PCD, and to provide advice regarding patients who do not have
a definitive diagnosis but diagnostic tests suggest that the diagnosis is highly likely or inconclusive.
The methods are detailed in the supplementary material.
Results
The results of the evidence assessment gave rise to the recommendations listed in table 1.
TABLE 1 Evidence-based recommendations for the use of each of the six tests considered for primary ciliary dyskinesia (PCD)
diagnosis
Which patients should be referred for diagnostic testing?
Based on moderate confidence in the evidence:
1. We recommend that patients are tested for PCD if they have several of the following features: persistent wet cough; situs anomalies;
congenital cardiac defects; persistent rhinitis; chronic middle ear disease with or without hearing loss; a history in term infants of neonatal
upper and lower respiratory symptoms or neonatal intensive care admittance (strong recommendation)
2. Patients with normal situs presenting with other symptoms suggestive of PCD (as listed in recommendation 1) should be referred for
diagnostic testing (strong recommendation)
3. Siblings of patients should be tested for PCD, particularly if they have symptoms suggestive of PCD (as listed in recommendation 1) (strong
recommendation)
4. We recommend the use of combinations of distinct PCD symptoms and predictive tools (e.g. PICADAR) to identify patients for diagnostic
testing (weak recommendation)
In patients suspected of having PCD should nasal nitric oxide be used as a diagnostic tool?
Based on moderate confidence in the evidence, we recommend that:
1. Nasal nitric oxide measurement should be used as part of the diagnostic work-up of school children aged >6 years and adults suspected of
having PCD, preferably using a chemiluminescence analyser with a velum closure technique (strong recommendation)
2. In children aged <6 years suspected of having PCD, we suggest nasal nitric oxide measurement using tidal breathing as part of the
diagnostic work-up (weak recommendation)
Remark: we suggest that patients presenting with a strong clinical history should undergo further testing, even if nasal nitric oxide is
normal (weak recommendation)
In patients suspected of having PCD should HSVA be used as a diagnostic tool?
Based on low confidence in the evidence, we recommend:
1. HSVA, including ciliary beat frequency and beat pattern analysis, should be used as part of the diagnostic work-up of patients suspected of
having PCD (weak recommendation)
2. Ciliary beat frequency should not be used without assessment of ciliary beat pattern in diagnosing PCD (strong recommendation)
3. To improve diagnostic accuracy of HSVA, CBF/P assessment should be repeated after ALI culture (strong recommendation)
In patients suspected of having PCD should TEM be used as a diagnostic tool?
Based on low confidence in the evidence, we recommend:
1. Ciliary ultrastructure analysis by TEM should be used as part of the diagnostic work-up of patients suspected of having PCD (strong
recommendation)
2. Further diagnostic investigations should be performed in patients with normal ultrastructure if the clinical history is strong (strong
recommendation)#
3. In patients with hallmark ciliary ultrastructure defects for PCD further confirmatory diagnostic investigations are not required (strong
recommendation)¶
In patients suspected of having PCD, should genotyping be used as a diagnostic tool?
There were no studies that fulfilled inclusion criteria to answer this question. Statements to assist the clinician are made in the genetics
sections but these are not evidence based. Therefore, we could not make formal recommendations as for other diagnostic procedures.
However, we have provided a list of Task Force statements on genetics, which is based upon agreement between experts rather than
published evidence.
In patients suspected of having PCD, should immunofluorescence be used as a diagnostic tool?
There were no studies that fulfilled inclusion criteria to answer this question. Statements to assist the clinician are made in the
immunofluorescence sections but these are not evidence based. Therefore, we could not make formal recommendations as for other
diagnostic procedures. However, we have provided a list of Task Force statements on immunofluorescence, based upon agreement between
experts rather than published evidence.
TEM: transmission electron microscopy; HSVA: high-speed video microscopy analysis. #: normal ciliary ultrastructure, as resolvable by TEM,
does not exclude the diagnosis of PCD (16% PCD-positive patients have TEM without a detectable defect); ¶: patients with hallmark ciliary
ultrastructure defects for PCD (absence of outer dynein arms, combined absence of inner and outer dynein arms, inner dynein arm absence
combined with microtubular disarrangement) assessed by TEM almost always have PCD (false-positive results are very rare ≈0.7%). CBF/P:
ciliary beat frequency/pattern; ALI: air–liquid interface.
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Clinical features
Summary of recommendations
Which patients should be referred for diagnostic testing?
Based on moderate confidence in the evidence:
1) We recommend that patients are tested for PCD if they have several of the following features: persistent
wet cough; situs anomalies; congenital cardiac defects; persistent rhinitis; chronic middle ear disease with
or without hearing loss; a history in term infants of neonatal upper and lower respiratory symptoms or
neonatal intensive care admittance (strong recommendation).
2) Patients with normal situs presenting with other symptoms suggestive of PCD should be referred for
diagnostic testing (strong recommendation).
3) Siblings of patients should be tested for PCD, particularly if they have symptoms suggestive of PCD
(strong recommendation).
4) We recommend the use of combinations of distinct PCD symptoms and predictive tools (e.g. PICADAR)
to identify patients for diagnostic testing (weak recommendation).
Review of evidence directly addressing the question “in patients suspected of having PCD, which
clinical features predict a positive diagnosis”?
Our search identified 1269 studies of which two directly answered the question and were included in the
quantitative synthesis (figure S1) and an additional six contributed to the narrative review. We excluded
1217 publications based on titles and abstracts. After full text review we excluded 44 of the remaining 52
studies because they did not fulfil the inclusion criteria (table S3).
Two studies, BEHAN et al. [10] and SHAPIRO et al. [11], were suitable to provide evidence for our
recommendations. They included 1408 patients (table 2).
BEHAN et al. [10] analysed data from 868 consecutive paediatric and adult patients. 227 with inconclusive
or incomplete results were excluded, leaving 641 for analysis. All patient data were collected through a
proforma completed by a clinician prior to the diagnostic testing. They reported sensitivity and specificity
of a large range of clinical features (table 2 and table S3). Wet cough did not discriminate well between
PCD positive and negative patients (sensitivity 0.93, specificity 0.15). Because it was the main reason for
referral, it was present in virtually all patients. Neonatal chest symptoms and neonatal rhinitis had a high
specificity (0.83 and 0.94), but a lower sensitivity (0.27 and 0.75). The sensitivity and specificity for 25
clinical features are summarised in table 2 and described in detail in the supplementary material.
In addition to reporting on single symptoms, BEHAN et al. [10] developed a seven-point questionnaire-based
prediction tool (PICADAR), to help predict the likelihood that a patient referred for evaluation of persistent
wet cough has PCD. PICADAR was internally and externally (in a second cohort) validated and is the first
clinical prediction tool developed for PCD. The score ranged from 0 to 14. Sensitivity and specificity of a
score of >5 were 0.90 and 0.75, respectively, clearly better than single symptoms.
SHAPIRO et al. [11] analysed data from 767 consecutive paediatric and adult patients. Information on situs
was determined by physicians at local consortium sites through review of radiology, surgery and
cardiology reports and radiology images from participant medical records. Patients were divided into three
situs categories: situs solitus, situs inversus and situs ambiguous (including heterotaxy).
Situs abnormalities were reported by BEHAN et al. [10] and SHAPIRO et al. [11] for a total of 1048 patients.
The pooled sensitivity and specificity for the two papers (for any situs abnormality) was 0.508 and 0.939,
respectively (table S3).
Narrative review of additional evidence
LEIGH et al. [12] described a prospective cohort of 534 children with high suspicion of PCD, among whom
many had a pre-existing diagnosis of PCD. Experts defined a priori and tested five clinical features
apparent in early childhood and found four, either alone or in combination, to be predictive of PCD:
1) unexplained neonatal respiratory distress with supplemental oxygen requirement for >24 h in term
infants; 2) early-onset, year-round wet cough; 3) early-onset year-round nasal congestion; and 4) laterality
defects [12]. NOLL et al. [13] described a retrospective cohort of 323 patients with chronic cough referred
for ciliary function analyses, and reported high specificity (>0.9) for neonatal respiratory distress,
persistent otitis media, situs inversus and bronchiectasis. CHIN et al. [14] retrospectively reviewed records
of 118 patients referred for electron microscopy because of suspected PCD, and compared combinations of
symptoms between patients with abnormal and normal electron microscopy, while excluding uncertain
cases. They found more sino-nasal, middle ear and pulmonary symptoms in the abnormal group [11].
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BEUCHER et al. [15] compared patients with abnormal and normal electron microscopy in a retrospective
cohort of 89 children suspected of PCD, excluding 21 uncertain cases and found that only situs inversus
differed significantly between the groups. PIFFERI et al. [16] compared clinical symptoms in 98 patients
with primary PCD versus secondary ciliary dyskinesia and statistically significant differences were found
for situs inversus and severity of bronchiectasis. In the only publication that focused on neonates,
MULLOWNEY et al. [17] compared neonatal symptoms between 46 PCD patients and 46 controls with a
history of neonatal respiratory distress syndrome, and found that lobar collapse, situs inversus and
prolonged oxygen need were more common in infants with PCD. The combination of situs inversus, lobar
collapse or oxygen need for >2 days had 87% (95% CI 74–94) sensitivity and 96% (85–99) specificity for
PCD. A systematic review by GOUTAKI et al. [18] describes other case–control or case series studies on
prevalence of clinical symptoms in PCD, which do not fulfil the inclusion criteria for this study. All
studies are from developed countries, and it is probable that the predictive value of some symptoms would
be different depending on geographical region; for example, sensitivity and specificity of bronchiectasis will
be different in sub-Saharan Africa where bronchiectasis due to tuberculosis is common.
Key unanswered questions and research needs
Further research is needed using prospective cohort studies of patients referred with suspicion of PCD in
whom clinical features are assessed in a standardised way before they are diagnosed. Analyses must be
stratified by age. In particular, there is a need for prospective studies of neonates with neonatal respiratory
distress syndrome. In addition, it might be helpful to combine information into clinical prediction scores,
TABLE 2 Summary of reported clinical manifestations in studies included in the quantitative
analysis
Clinical manifestation Sensitivity (95% CI) Specificity (95% CI)
Neonatal manifestations
Neonatal chest symptoms 0.75 (0.63–0.84) 0.83 (0.79–0.84)
Neonatal rhinitis 0.27 (0.17–0.38) 0.94 (0.91–0.95)
Neonatal respiratory support 0.41 (0.30–0.53) 0.93 (0.90–0.95)
Neonatal unit admission 0.61 (0.49–0.72) 0.86 (0.83–0.89)
Upper respiratory manifestations after the post-natal period
Chronic rhinitis 0.81 (0.70–0.89) 0.43 (0.38–0.47)
Chronic serious otitis media 0.57 (0.45–0.69) 0.81(0.77–0.84)
Chronic acute otitis media 0.33 (0.23–0.45) 0.75 (0.71–0.79)
Hearing loss 0.49 (0.38–0.61) 0.84 (0.81–0.87)
Chronic ear perforation 0.12 (0.06–0.22) 0.91 (0.88–0.93)
Ear surgery 0.32 (0.22–0.44) 0.86 (0.82–0.88)
Chronic sinusitis 0.28 (0.19–0.40) 0.76 (0.72–0.79)
Lower respiratory manifestations after the post-natal period
Chronic wet cough 0.93 (0.84–0.98) 0.15 (0.12–0.18)
Recurrent wheeze 0.48 (0.36–0.60) 0.62 (0.57–0.65)
Previous pneumonia 0.41 (0.30–0.53) 0.65 (0.61–0.69)
Bronchiectasis 0.29 (0.20–0.41) 0.68 (0.64–0.72)
Other manifestations (various ages)
Situs anomalies# 0.51 (0.46–0.56) 0.94 (0.92–0.95)
Congenital heart disease 0.08 (0.03–0.17) 0.98 (0.97–0.99)
Developmental delay 0.11 (0.05–0.20) 0.94 (0.91–0.96)
Hydrocephalus 0.01 (0.00–0.08) 0.99 (0.98–1.00)
Subfertility¶ 0.91 (0.57–1.00) 0.82 (0.74–0.87)
Family history (any age)
Primary ciliary dyskinesia in siblings 0.24 (0.15–0.35) 0.98 (0.97–0.99)
Primary ciliary dyskinesia in extended family 0.05 (0.02–0.14) 0.99 (0.97–1.00)
Asthma 0.16 (0.09–0.27) 0.66 (0.62–0.70)
Bronchiectasis 0.04 (0.01–0.12) 0.96 (0.93–0.97)
Otitis media 0.07 (0.02–0.16) 0.89 (0.86–0.92)
Clinical scores
PICADAR score >5 0.90 (0.81–0.96) 0.75 (0.70–0.80)
All data from BEHAN et al. [10] (641 eligible referrals, 75 (12%) had primary ciliary dyskinesia). #: data on
situs anomalies are from BEHAN et al. [10] and SHAPIRO et al. [11] (767 referrals); ¶: data on subfertility are
from a subgroup of 152 referrals where 11 (7%) had primary ciliary dyskinesia.
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using state of the art approaches [17]. Validity of the different clinical features is also likely to vary
depending on the population under evaluation. For instance, positive and negative predictive values of the
symptoms strongly depend on the prevalence of the disease in the referral population and will be poorer
in populations with a lower prevalence (i.e. in primary or secondary care compared to PCD referral
centres). Sensitivity and specificity (shown in the table 2) do not depend on prevalence. Nevertheless, the
mix in PCD phenotypes, and therefore the usefulness of different symptoms for prediction of PCD, is
likely to differ between patients attending specialised clinics (e.g. ear nose and throat, pulmonology, and
cardiology). For instance, while chronic cough will not distinguish between patients with and without PCD
in a pulmonology clinic, chronic ear, nose and throat symptoms will not be distinctive in an ear, nose and
throat clinic where (nearly) every patient has these complaints, and cardiac defects will not distinguish in a
cardiology setting. Another factor to consider is that clinical features might differ between genetic variants
(e.g. patients with CCNO variants show no situs anomalies but increased female infertility), so results vary
with differences in prevalence of specific mutations in the evaluated population. Therefore, studies must be
performed in specific healthcare settings and study populations, and consider age, sex and genetic
abnormalities.
Summary
Relevant literature answering our question was extremely scarce (only two papers, of which one reported
only on situs inversus), and results did not take severity of symptoms into account or stratify by age.
Overall confidence in their results is moderate mainly because diagnostic performance does not inform
downstream consequences of further clinical management based on the assessment of these symptoms.
Results suggest that clinical symptoms may help to distinguish between patients with and without PCD,
but the positive predictive value (how many patients with a specific symptom have the disease) of single
symptoms is low. Instead, the combination of suggestive symptoms might discriminate better, but this
needs further study in different populations.
Wet cough starting in early childhood has been used as the initial selection criterion in most PCD studies.
Therefore, it has a low discriminative value due to its high prevalence in both PCD positive and negative
individuals recruited to these studies.
Nasal nitric oxide
Summary of recommendations
In patients suspected of having PCD, should nNO be used as a diagnostic tool?
Based on moderate confidence in the evidence, we recommend that:
1) nNO measurement should be used as part of the diagnostic work-up of schoolchildren aged >6 years
and adults suspected of having PCD, preferably using a chemiluminescence analyser with a velum closure
technique (strong recommendation).
2) In children aged <6 years suspected of having PCD, we suggest nNO measurement using tidal breathing
as part of the diagnostic work-up (weak recommendation).
We suggest that patients presenting with a strong clinical history should undergo further testing, even if
nNO is normal (weak recommendation).
Explanation of the diagnostic test
nNO is extremely low in PCD when compared to healthy and disease controls, for unknown reasons [19].
The accuracy of nNO as a diagnostic test in PCD varies by type of analyser, sampling method and age of
patient [20].
Current guidelines recommend aspiration of gas from one nostril with gas entrained via the other naris to
measure nNO using a stationary chemiluminescence analyser during a velum closure, such as breath hold or
oral exhalation against resistance. The reading should be obtained from a technically acceptable plateau
reading [21]. Whilst measurement during velum closure by chemiluminescence analyser is considered the
“gold standard”, this manoeuvre is not possible in all situations. In young children measurements during
tidal breathing have been reported [22, 23]. Electromechanical portable analysers [23] are used where
stationary chemiluminescence analysers are not available. There is currently no consensus over what
threshold constitutes a positive or negative cut-off.
Although analysers report readings in parts per billion (ppb), this is influenced by the machine sampling
rate, so the concentration is converted to nL·min−1 by the formula nL/min=ppb×sampling rate in L·min−1.
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Review of evidence directly addressing the question “in patients suspected of having PCD, should
nNO be used as a diagnostic tool?”
Our search identified 98 studies, of which 23 met inclusion criteria for qualitative assessment. Of these, four
papers (n=588 patients) assessed nNO in a cohort of patients suspected of PCD who eventually received either
a positive or negative diagnosis, directly addressing the question (table 3 and table S4). The other 19 papers
were excluded from informing the recommendations, but contributed to the narrative review (table S5).
MARTHIN et al. [24] measured nNO during breath hold, exhalation against resistance and tidal breathing.
Sensitivity ranged from 0.92 (for breath hold) to 1.0 (oral exhalation against resistance) and specificity ranged
from 0.80 (tidal breathing) to 0.96 (breath hold) [24]. LEIGH et al. [25] developed a threshold of 77 nL·min−1
using data from a PCD specialist centre and then trialled this cut-off in 155 consecutive patients at other sites.
Comparing PCD-positive to indeterminate patients provided a sensitivity of 0.99 and specificity of 0.75 [25].
Lower specificity was because the diagnostic protocol only included electron microscopy and genetics, thus
missing a number of true PCD cases (“indeterminate” rather than PCD negative). BEYDON et al. [22] reported a
sensitivity of 0.91 and specificity of 0.86 for velum closure (cut-off 82 nL·min−1) and 0.90 and 0.97 for tidal
breathing (40 nL·min−1; mean of five peaks). JACKSON et al. [26] used a cut-off of 30 nL·min−1 and reported
sensitivity and specificity of 0.91 and 0.96, respectively, to distinguish 34 PCD-positive from 267 PCD-negative
patients. Further methodological details of these four studies are included in table S4.
Overall confidence in this evidence is moderate mainly because diagnostic performance is not informative
of downstream consequences of further clinical management.
Narrative review of additional evidence
A number of studies that did not meet the inclusion criteria for making recommendations addressed
important issues. Several studies used alternative methods for the measurement of nNO that do not use the
American Thoracic Society/ERS guideline “gold standard” (velum closure, stationary analyser) [21]. Tidal
breathing manoeuvres are useful, especially in those unable to perform a velum closure, but may be less
discriminative. The study by MARTHIN et al. [23] of consecutive referrals found breath hold sensitivity of 0.92
and specificity of 0.96 compared to tidal breathing values of 0.93 and 0.80 (thresholds were breath hold –
52.5 nL·min−1 and tidal breathing –47.4 nL·min−1). However, BEYDON et al. [22] found increased accuracy of
tidal breathing (37.9 nL·min−1 threshold; sensitivity 0.94, specificity 0.92) versus velum closure
(82.2 nL·min−1, sensitivity 0.91, specificity 0.86). Measurement using portable analysers was assessed in two
case–control studies. Using a portable analyser, MARTHIN et al. [23] compared PCD patients to those with
cystic fibrosis and healthy controls. They found a sensitivity and specificity of 1.0 and 0.95, respectively, for
breath hold (64 nL·min−1 threshold) and 1.0 and 1.0, respectively, for tidal breathing (43 nL·min−1) [23].
HARRIS et al. [27] studied 13 PCD and 37 disease control/healthy patients using tidal breathing and a portable
analyser with a cut-off of 30 nL·min−1. Sensitivity and specificity were 1.0 and 0.95, respectively [27].
Measurement of nNO in young children is possible; however, discrimination between PCD patients and
controls is reduced as nNO is inversely proportional to age in healthy patients <12 years of age [28, 29].
One study showed that velum closure was possible in children as young as 3.9 years [20]. However, the
majority of very young children are unable to co-operate with velum closure and so tidal breathing
TABLE 3 Summary of diagnostic accuracy of nasal nitric oxide from measurements in consecutive patients suspected of
primary ciliary dyskinesia (PCD)
First author [ref.] Study population Sampling method Threshold
nL·min−1
Sensitivity
(95% CI)
Specificity
(95% CI)
MARTHIN [24] 117 referrals (PCD: n=14) Breath hold: n=58 52.5 0.92 (0.62–0.998) 0.96 (0.85–0.995)
Oral exhalation against
resistance: n=37
72.6 1.0 (0.54–1.0) 0.94 (0.79–0.99)
Tidal breathing: n=97 47.4 0.93 (0.66–0.998) 0.80 (0.69–0.88)
LEIGH [25] 155 referrals (PCD: n=71;
indeterminate: n=84)
Oral exhalation, velum
closure: n=155
77 0.99 (0.92–0.9996) 0.75 (0.64–0.84)
BEYDON [22] 86 referrals: (PCD: n=49;
non-PCD: n=37)
Velum closure: n=74 82.2 0.91 (0.79–0.98)
0.90 (0.78–0.97)
0.86 (0.68–0.96)
0.97 (0.86–0.999)
Tidal breathing (five
peaks): n=86
40
JACKSON [26] 301 referrals: (PCD: n=34;
non-PCD: n=267)
Velum closure (breath hold
or oral exhalation): n=301
30 0.90 (0.74–0.98) 0.95 (0.90–0.98)
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measurements have to be used. The studies by MARTHIN et al. [23] and BEYDON et al. [22] suggest that tidal
breathing may produce similar accuracy to velum closure in adults; however, this has not been shown in
children. The study of 117 consecutive referrals of all ages by MARTHIN et al. [23] found that the
false-positive rate for children <6 years of age using tidal breathing was 39%.
There is increasing evidence that some genetic mutations causing PCD may be associated with subtle beating
abnormalities and nNO levels within the normal range. This includes two studies of PCD individuals with
mutations encoding radial spoke head proteins, and one study in PCD individuals with abnormal nexin link
composition due to GAS8 mutations associated with an nNO higher than usually seen in PCD [30–32]. This
may partially explain the variability of the results and low diagnostic performance of nNO in some studies.
Key unanswered questions and research needs
Current evidence has shown that nNO is a useful test as part of the diagnostic process; however, there is
no consensus on appropriate thresholds. Likewise, standardised protocols and thresholds need to be
developed for tidal breathing, portable analysers and measurements, and normative data in younger
children, particularly those <6 years of age. Further work on genotype–phenotype correlation can help in
the interpretation of nNO levels in cases of diagnostic uncertainty in order to reduce the number of
false-negative test results. There is no evidence that can lead us to recommend which patients with a
normal nNO should be referred for further testing and this requires evaluation.
Summary
nNO is a highly accurate test for PCD when measured via a stationary chemiluminescence analyser using
velum closure techniques with a sensitivity and specificity of 0.90–1.0 and 0.75–0.97, respectively. Tidal
breathing technique or use of portable analysers are less sensitive and specific but may contribute to the
diagnostic decision. Different studies have used different methods and cut-off values making it difficult to
provide definite thresholds.
nNO is not sufficiently accurate to rule PCD in or out in isolation but considering that it is relatively easy
to perform, is noninvasive and is affordable, the panel considered that it should be used as part of the
diagnostic work-up of patients suspected of having PCD.
High-speed video analysis
Summary of recommendations
In patients suspected of having PCD, should HSVA be used as a diagnostic tool?
Based on low confidence in the evidence, we recommend:
1) HSVA, including ciliary beat frequency and beat pattern analysis, should be used as part of the
diagnostic work-up of patients suspected of having PCD (weak recommendation).
2) Ciliary beat frequency should not be used without assessment of ciliary beat pattern in diagnosing PCD
(strong recommendation).
To improve diagnostic accuracy of HSVA, CBF/p assessment should be repeated after air–liquid interface
culture (strong recommendation).
Explanation of the test
PCD is related to abnormal ciliary function [33], which can be analysed ex vivo by assessment of ciliary activity
in respiratory epithelium from the nose or bronchus. Ciliated cells can be observed immediately after sampling
[34–36] and again after a period of culturing to differentiate PCD from secondary dyskinesia [37–40]. A video
attached to a microscope records at high speeds (120–500 fps), and is replayed slower (30–60 fps) to review
ciliary beat pattern and measure ciliary beat frequency [41]. Most studies have used analysis by expert
microscopists, whilst several studies used computer analysis in an attempt to reduce subjectivity/observer bias.
HSVA provides a permanent record that can be used for audit, expert advice or research.
Review of evidence directly addressing the question “in patients suspected of having PCD, should
HSVA be used as a diagnostic tool?”
Our search identified 113 studies, of which 30 met inclusion criteria for qualitative assessment. (figure S1).
Two studies (650 patients) assessed HSVA in cohorts suspected of PCD who eventually received either
a positive or negative diagnosis, contributing to the evidence for recommendations (table 4). The other
28 papers did not meet the inclusion criteria for informing the recommendations, but contributed to our
narrative review (table S6).
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PAPON et al. [42] measured 12 parameters of ciliary beat pattern, including ciliary beat frequency. The
distance travelled by the cilia tip weighted by the percentage of beating edges had the best sensitivity (0.96)
and specificity (0.95) to distinguish 10 PCD positive from 15 PCD negative patients [42]. Using this
parameter in nine patients with previously inconclusive diagnoses, it was possible to support the diagnosis
of PCD in four cases and exclude it in two. JACKSON et al. [26] found a sensitivity and specificity of 1.00
and 0.93, respectively, for the combination of ciliary beat frequency measurement and beat pattern
evaluation in a cohort of 625 referrals, including 60 PCD positive patients.
Overall confidence in this evidence is low, mainly because diagnostic performance is not informative of
downstream consequences of further clinical management based on the assessment of HSVA and because
of study limitations (HSVA was widely used as part of the reference standard and lack of blinding).
Narrative review of additional evidence
To date, there is no standardised method for cell processing and analysis. Respiratory epithelium can be
collected using brush, curette or forceps, usually from the nose [43]. Ciliary function varies under differing
conditions; for example, temperature and pH, with some centres measuring at 37oC [26, 40, 42, 44] and others
at lower temperatures [35, 37, 45]. This will affect ciliary function and all centres need to define their own
normative data until a consensus is reached to allow standardisation of methods and reporting between centres.
Equivocal results or abnormal results require repeat sampling or re-analysis following cell culture [38, 40,
46, 47] since secondary defects are common. In a series of 712 patients, JORISSEN et al. [47] assessed ciliary
beat frequency and ciliary coordination in suspension culture (i.e. spheroids). 642 (20%) non-PCD patients
demonstrated abnormal ciliary activity before culture, but after culture 100% had normal ciliary activity.
Conversely, in biopsies of 70 PCD patients (evaluable in 56), 20% had a normal ciliary beat frequency and
10% had coordinated ciliary activity before culture. After culture, normal ciliary beat frequency was found
in 7% of PCD patients but ciliary function was never normally coordinated, making this parameter more
sensitive and specific than ciliary beat frequency measurement [47]. HIRST et al. [40] reported ciliary beat
frequency and pattern before and after air–liquid interface cultures in 158 patients. Before culture, most
PCD and non-PCD patients exhibited a degree of functional ciliary abnormalities. After air–liquid
interface culture, normal ciliary beat pattern was observed in all non-PCD patients, whilst in PCD patients
ciliary beat pattern was uniformly abnormal. PIFFERI et al. [46] assessed the results of ciliary beat pattern
and frequency analysis after suspension culture (i.e. spheroids) in nine subjects with inconclusive results
on nasal brushings. After culture, four patients had abnormal ciliary beat pattern suggesting PCD
diagnosis, two had secondary dyskinesia ciliary beat pattern and three remained inconclusive. Culture
techniques are limited by success rates ranging from 54% to 83% [26, 37, 40].
Ciliary beat frequency measurement does not adequately differentiate PCD from non-PCD unless
combined with ciliary beat pattern assessment. STANNARD et al. [48] found a sensitivity and specificity of
0.97 and 0.95, respectively, for the percentage of dyskinetic epithelial edges whilst ciliary beat frequency
alone only yielded a sensitivity and specificity of 0.87 and 0.77, respectively. Moreover, ciliary beat
frequency may be slow, normal or increased in PCD depending on the genotype [45].
Some ultrastructural defects and genetic mutations causing PCD may be associated with specific patterns
of ciliary beating. In a cohort of 56 children, CHILVERS et al. [44] reported virtually immotile cilia in
patients with either a: combined inner and outer dynein arm (IDA and ODA) defect or an isolated ODA
defect; stiff beat pattern in patients with either an isolated IDA or radial spoke with an IDA defect; and
circular beating cilia in patients with a ciliary transposition defect. RAIDT et al. [45] studied ciliary beat
pattern according to the genetic variants of PCD. Although numbers associated with some genes were
extremely small, the data supports the linking of a PCD causing gene with particular ciliary beat patterns:
cilia from patients with mutations in ODA causing genes (DNAH5, DNAI1, DNAI2, ARMC4) showed
minimal residual movements. In patients with DNAH11 mutations (normal ultrastructure), cilia exhibited
TABLE 4 Summary of diagnostic accuracy of high-speed video analysis (HSVA) from evaluation in consecutive patients
suspected of primary ciliary dyskinesia (PCD)
First author [ref.] Study
population
Cilia assessment method Sensitivity (95% CI) Specificity (95% CI)
PAPON [42] 25 referrals
(10 PCD positive)
HSVA beat frequency and quantitative
measurements of beat pattern
0.96 (0.89–0.98) 0.95 (0.91–0.98)
JACKSON [26] 625 referrals
(60 PCD positive)
HSVA beat frequency and subjective pattern 1.0 (0.94–1.00) 0.93 (0.91–0.95)
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a hyperkinetic ciliary beat pattern with reduced proximal axonemal bending. Some genetic defects, such as
GAS8 mutations, can result in subtle defects that are hardly detectable by HSVA [30].
Key unanswered questions and research needs
Current evidence suggests that HSVA is a useful test as part of the diagnostic process, but there is no
consensus on appropriate cell processing and method of ciliary assessment. Likewise, standardised
protocols and thresholds need to be developed for ex vivo analysis of ciliary beat pattern. Further work on
genotype/ultrastructural phenotype correlation can help in interpretation of HSVA parameters in cases of
diagnostic uncertainty.
Summary
HSVA is an accurate test for PCD when performed by experienced observers combining ciliary beat
frequency measurement and pattern analysis (sensitivity and specificity of 0.95–1.00 and 0.93–0.95,
respectively). Culturing the respiratory cells may contribute to improve the accuracy of HSVA, in
particular to rule out false positives.
HSVA is not sufficiently standardised to rule PCD in isolation in or out. Considering that optimal
conditions in functional evaluation of cilia remains to be defined, the panel considered that HSVA should
be performed by experienced staff as part of the diagnostic work-up of patients suspected of having PCD.
This might impair the availability of the test in many centres.
Transmission electron microscopy
Summary of recommendations
In patients suspected of having PCD, should TEM be used as a diagnostic tool? Based on low confidence
in the evidence, we recommend:
1) Ciliary ultrastructure analysis by transmission electron microscopy should be used as part of the
diagnostic work-up of patients suspected of having PCD (strong recommendation).
2) Further diagnostic investigations should be performed in patients with normal ultrastructure if the
clinical history is strong (strong recommendation).
3) In patients with hallmark ciliary ultrastructure defects for PCD further confirmatory diagnostic
investigations are not required (strong recommendation).
Explanation of the diagnostic test
In 1976, AFZELIUS [33] demonstrated that TEM could be used to detect ultrastructural defects of cilia in
patients with primary ciliary dyskinesia. Subsequently, for many years TEM was considered the “gold
standard” diagnostic test for PCD. However, several genetic studies have demonstrated that an increasing
number of distinct genetic PCD sub-types (e.g. due to DNAH11 mutations) cannot be diagnosed by TEM
[49]. Thus, TEM cannot rule out PCD diagnosis.
Respiratory epithelium is usually sampled from the inferior turbinate of the nose by brush or curette
biopsy or from the lower respiratory tract during bronchoscopy. The epithelium is chemically fixed with
glutaraldehyde, processed and embedded into blocks, which are sectioned with an ultramicrotome.
Staining with heavy metals (lead and uranyl) provides contrast. Assessment of cilia from healthy cells in
transverse sections is made using TEM [50, 51]. The number of cilia and cells analysed varies between
centres; unless sufficient numbers are assessed, defects caused by mutations in genes that cause
intermittent defects are likely to be missed. Considerable expertise is required to perform TEM and
interpret results; expenditure for equipment and running costs are high.
The normal ultrastructural ciliary arrangement in a transverse section is a circle of nine microtubule
doublets, each with a pair of dynein arms, plus a central pair of microtubules (figure 1). There are a number
of ultrastructural phenotypes associated with a diagnosis of PCD (figure 2). The majority of cases are due to
a lack of dynein arms; other defects include disorganisation of the microtubular doublets or loss of the
central microtubular pair (table 5). Some patients with PCD have apparently normal ciliary ultrastructure, as
seen by TEM. Secondary ciliary dyskinesia can be associated with transient ultrastructural abnormalities,
such as compound cilia, axonemal blebs or additional tubules, which must not be confused with PCD.
Review of evidence directly addressing the question “in patients suspected of having PCD, should
TEM be used as a diagnostic tool?”
We identified and screened 370 studies, of which the full texts of 46 were assessed for eligibility. Of the 17
that met inclusion criteria for qualitative assessment (table S7), 11 papers (3200 patients) assessed TEM in
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a cohort of patients suspected of PCD who eventually received either a positive or negative diagnosis,
contributing to the evidence for recommendations (figure S1).
Tables 5 and 6 summarise the 11 studies addressing the question. The sensitivity calculated from each study
ranged between 0.71 and 1.00 and the specificity between 0.92 and 1.00. There were five false-positive
patients in two studies. PAPON et al. [42] identified two false-positive results; one was a child with severe
asthma without recurrent upper airway infection who had short or absent ODA concerning 44% of nasal
cilia and 90% of bronchial cilia, the other an adult with situs inversus and nasal polyposis without lower
airway symptoms who had absent IDA without microtubular disorganisation (personal communication).
MUNKHOLM et al. [57] identified three false positives in individuals each eventually thought to have
secondary ciliary dyskinesia, two of whose clinical phenotype improved becoming asymptomatic and a
third who had severe asthma. Total specificity, when combining all 11 studies, was >0.99.
The quality of evidence was rated low because diagnostic performance is not informative of downstream
consequences of further clinical management and because of study limitations (frequent use of TEM in
the reference standard and lack of blinding). However, the very low rate of false positives and the very
high specificity of TEM led to strong recommendations.
Narrative review of additional evidence
Assessment of the proportion of TEM defects in patients with PCD was made following a review of all
manuscripts (post 1996) describing a cohort of more than 50 individuals [26, 42, 48, 56, 58, 59] (table 4).
ODA defects (26–59%) and combined ODA and IDA defects (6–39%) were the most commonly observed.
The recommendations below refer to common hallmark defects (absence of ODA, combined absence of
IDA and ODA, IDA absence combined with microtubular disarrangement). Isolated IDA defects by TEM
are controversial. Several studies acknowledge that IDA are difficult to visualise by TEM [42, 60, 61] and
repeat analysis has been recommended before confirming a diagnosis [62]. For central pair defects the
ciliary defect is usually present in a minority of cilia making the diagnosis difficult especially since patients
do not have situs inversus.
Evidence for add on techniques to improve electron microscopy in the diagnosis of PCD was reviewed.
Computer-assisted analysis has been reported to enhance the visualisation of dynein arms and
consequently improve the sensitivity of electron microscopy [60, 61]. Electron tomography is an advanced
TEM technique allowing visualisation of structures in three-dimension. A series of TEM images are
acquired by tilting the specimen stage at regular increments around two perpendicular axes. Images from
both tilt series are then aligned into a single three-dimensional high-resolution projection. If a structural
feature is repeated within a tomogram, it can be enhanced through sub-tomographic averaging; a
technique in which software extracts the chosen common features and makes comparison by cross
correlation. Electron tomography has been shown to improve three-dimensional visualisation and
resolution of cilia allowing identification of patients with HYDIN and DNAH11 gene defects in a research
setting [63]. The use of tomography for diagnosis has not been evaluated.
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FIGURE 1 Diagram of normal ultrastructure of the ciliary axoneme in transverse section.
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Our evidence review considered only conclusive results. Reported rates of inconclusive results ranged from
1.7% to 28.6% [26, 37, 39, 58]. This was attributed to poor sampling technique or the presence of
secondary changes to the cilia. Seven of the 11 studies reported measures to avoid sampling during or
immediately after an upper respiratory tract infection to improve adequacy and minimise secondary ciliary
ultrastructural change.
Cell culture techniques that induce ciliogenesis from human biopsies are used in a number of PCD
diagnostic centres. Two techniques to induce basal cell proliferation and ciliated cell differentiation have
been described for PCD diagnosis [37, 40]. JORISSEN et al. [37] established a submerged culture technique
and the air–liquid interface technique was first described for PCD diagnosis by HIRST et al. [40]. Both
methods have shown that the TEM axoneme structure is conserved after cell culture in normal and PCD
subjects, and they have been shown to reduce secondary damage [37, 40]. TEM following culture has the
potential to aid diagnosis of reduced generation of multiple motile cilia [64].
Key unanswered questions and research needs
Basic scientific research must improve the technique of TEM and identify PCD in those with “normal
ultrastructure”. The diagnostic community requires standardised protocols and consensus on terminology,
a) c)
b) d)
FIGURE 2 Electron microscopy images of primary ciliary dyskinesia defects. a) Inner and outer dynein arm defect, b) outer dynein arm defect, c)
inner dynein arm and microtubular disarrangement and d) central pair and transposition defect.
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especially regarding the number and proportion of cilia required to make a diagnosis. True relevance and
prevalence of IDA and other rare defects needs to be confirmed.
Summary
TEM is a highly specific test to confirm a diagnosis of PCD and is a key part of the diagnostic work.
However, some patients with PCD have apparently normal ultrastructure and therefore TEM should not
be used in isolation to exclude a diagnosis.
All 11 studies were retrospective analyses of cohorts of patients with clinical suspicion of PCD, the largest
of which spanned time-periods of 20 years [54, 56]. Further downgrading was due to the use of TEM as
the reference standard and lack of blinding, resulting in grading of evidence as low.
Genetics
In patients suspected of having PCD, should genotyping be used as a diagnostic tool? There were no
studies that fulfilled the inclusion criteria to answer this question.
Explanation of the diagnostic test
PCD is a genetically heterogeneous disorder. As with autosomal recessive disorders in general, disease is
more likely in offspring from consanguineous relationships, and has a 1:4 probability from any conception
where both parents are healthy carriers. To date, mutations in more than 30 genes have been reported to
cause PCD (table 7). A more detailed explanation of the PCD-associated genes is presented in the
supplementary material.
To establish the genetic diagnosis, non-ambiguous bi-allelic mutations in autosomal recessive PCD and
hemizygous mutations in X-linked PCD should be identified. The majority of reported mutations are
nonsense, frameshift or splice mutations while missense mutations are identified in a minority of cases.
Most of the mutations are private, but founder mutations (e.g. in DNAI1 [105] and DNAH5 [95]) and
TABLE 5 Characteristics of the ultrastructural defects described in nine studies directly addressing the PICO question using
transmission electron microscopy to diagnose primary ciliary dyskinesia
PAPON [54] STANNARD [48] OLIN [58] SHOEMARK [56] BOON [59] JACKSON [26] Total
Subjects n 190 68 155 214 138 57
Isolated outer dynein arm defect 33 26 54 41 59 46 44
Inner and outer dynein arm defect 32 34 23 24 6 39 25
Inner dynein arm with microtubular
disorganisation
13 6 7 9 16 9 10
Isolated inner dynein arm defect 4 21 15 13 0 0 9
Central pair defect 19 13 1 12 14 7 8
Other# 3 5 1
Total n 190 68 155 214 138 57
Data are presented as percentage, unless otherwise stated. #: include ciliary aplasia, disorientation and extra microtubules.
TABLE 6 Sensitivity and specificity of the 11 studies directly addressing the PICO question using transmission electron
microscopy to diagnose primary ciliary dyskinesia
First author [ref.] Study population n Conclusive diagnostic result reached n Sensitivity (95% CI) Specificity (95% CI)
JORISSEN [37] 812 468 0.71 (0.61–0.81) 1.0 (0.99–1.0)
PIFFERI [52] 64 62 0.75 (0.48–0.93) 1.0 (0.93–1.0)
PIFFERI [39] 59 56 0.77 (0.50–0.93) 1.0 (0.91–1.0)
HIRST [53] 231 187 1.0 (0.88–1.0) 1.0 (0.98–1.0)
PAPON [54] 1149 793 0.82 (0.77–0.86) 1.0 (0.99–1.0)
OLM [55] 24 24 0.92 (0.62–1.0) 1.0 (0.74–1.0)
PAPON [42] 34 28 0.83 (0.52–0.98) 1.0 (0.79–1.0)
SHOEMARK [56] 1182 1031 0.88 (0.83–0.91) 1.0 (1.0–1.0)
HIRST [40] 165 122 0.96 (0.87–1.0) 1.0 (0.95–1.0)
MUNKHOLM [57] 239 61 0.83 (0.61–0.95) 0.92 (0.79–0.98)
JACKSON [26] 868 368 0.79 (0.68–0.88) 1.0 (0.99–1.0)
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TABLE 7 Overview of primary ciliary dyskinesia causing genes and their associated findings by transmission electron
microscopy (TEM) and immunofluorescence analyses
Gene [Ref.] Locus TEM Immunofluorescence
DNAH5 [65] 5p15 ODA Absent DNAH5 and DNAH9 [67, 94, 95]
DNAH11 [49] 7p15–21 Normal DNAH11 is absent in patients with DNAH11 loss-of
function mutations, DNAH5 and DNALI1 present [96, 97]
DNAI1 [66] 9p21-p13 ODA DNAH5 staining may be present proximally but
absent distally,
DNAH9 absent within the ciliary axonemes [67, 94]
DNAI2 [67] 17q25.1 ODA DNAH5, DNAI2 and DNAH9 absent or aberrant [67]
NME8 (TXNDC3) [68] 7p14.1 ODA Not reported
DNAL1 [69] 14q24.3 ODA Not reported
CCDC151 [70] 19p13.2 ODA DNAH5, CDC151, CCDC114 and ARMC4 absent,
DNALI1 present [70]
CCDC114 [71] 19q13.33 ODA CCDC114 severely reduced, DNAH5 absent, DNALI1
undisturbed [71]
ARMC4 [72] 10p21 ODA Reduced ARMC4 staining along cilia, complete distal loss
of DNAH5, DNAH5 only on proximal ciliary end, DNALI1
present [72, 98]
CCDC103 [73] 17q12 ODA+IDA DNAH5, DNAH9 and DNALI1 are missing or
reduced in a small number of patients [73]
DYX1C1 (DNAAF4) [74] 15q21 ODA+IDA DNAH5, DNAH9 and DNAI2 absent [74]
SPAG1 [75] 8q22 ODA+IDA Absent DNAH5 and DNALI1 [75]
LRRC6 [76] 8q24 ODA+IDA LRRC6, DNALI1 and DNAI2 absent or very
reduced [76, 82, 99]
DNAAF2 (KTU) [77] 14q21.3 ODA+IDA DNAH5 and DNAI2 absent distally with some
residual staining,
DNAH9 and DNALI1 absent [77]
DNAAF1 (LRRC50) [78, 79] 16q24 ODA+IDA DNAH5, DNAH9 and DNALI1 absent [79]
C21orf59 [80] 21q22.1 ODA+IDA DNAH5 and DNALI1 absent [80]
DNAAF3 [81] 19q13 ODA+IDA DNAH5, DNAH9 and DNALI1 absent [81]
ZMYND10 [82] 3p21.3 ODA+IDA DNAH5, DNAI2 and DNALI1 absent [82, 100]
DNAAF5 (HEATR2) [83] 7p22.3 ODA+IDA DNAI1, DNAH5 and DNALI1 absent,
HEATR2 reduced [83, 101]
HYDIN [84] 16q22 Normal/subtle: increased
frequency of transposition defects
Normal IDA (DNALI1) and ODA (DNAH5) [84]
RSPH1 [32] 21q22.3 Intermittent central pair/transposition
defects
RSPH1 and RSPH9 absent, RSPH4A present [32, 86, 102]
RSPH3 [85] 6q25.3 Intermittent central pair/near
absence of radial spokes
RSPH3 and RSPH11 absent, RSPH1, RSPH4A and RSPH23
present (RSPH9 not reported),
DNALI1 present [85]
RSPH9 [86] 6p21 Intermittent central pair defect/
transposition
Absent RSPH9, RSPH1 and RSPH4A present [86]
RSPH4A [86] 6q22 Intermittent central pair defect/
transposition
RSPH4A, RSPH9 and RSPH1 absent [86]
DRC1 (CCDC164) [87] 2p23 Normal/subtle: N-DRC links missing
with occasional MT disorganisation
GAS8 and LRRC48 absent from ciliary axonemes [87]
GAS8 (DRC4) [30] 16q24.3 Normal/subtly abnormal: increased
frequency of MT misalignment
DNALI1 and DNAH5 present, GAS8 absent [30]
CCDC65 (DRC2) [88] 12q13.12 Normal/N-DRC links missing with
occasional MT disorganisation
CCDC65 and GAS8 reduced [88]
CCDC39 [89] 3q26 MT disorganisation+IDA Absent CCDC39 protein, ODA normal distribution (DNAH5,
DNAI2, DNAH9), DNALI1 (IDA) absent, GAS8 in cytoplasm
but absent from axoneme [89, 103]
CCDC40 [90] 17q25 MT disorganisation+IDA Absent CCDC39 protein, RSPH4A and ROPN1 L/RSP11
present in axonemes [90, 103]
RPGR# [91] Xp21.1 Variable Normal, DNAH5 and DNALI1 present [104]
OFD1¶ [92] Xp22 Unknown Not reported
CCNO [64] 5q11.2 Reduction of cilia number DNAH5 present, rootletin mislocated in deeper regions of
cytoplasm, CCNO not detectable [64]
MCIDAS [93] 5q11.2 Reduction of cilia number MCIDAS, CCNO, DNAH5, CCDC39 and CCDC78 absent [93]
ODA: outer dynein arm; IDA: inner dynein arm; N-DRC: nexin link-dynein regulatory complex; MT: microtubular. #: retinitis pigmentosa usually
detected in adult patients; ¶: rare syndromic phenotype.
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mutational hot spots (e.g. CCNO [106]) have been reported. The ranking of the effect of the mutations
should follow international recommendations [107]: benign (class 1), likely benign (class 2), unknown
significance (class 3), likely pathogenic (class 4), pathogenic (class 5).
The associations between genotype and structural defects documented by TEM and/or immunofluorescence
are well established, but much less is known about gene HSVA associations. With studies based on small
numbers of patients and often a limited number of videos per patient [45], there is insufficient data to
correlate mutations within a gene with dyskinesia phenotype. To date, our knowledge suggests that
disease-causing mutations in DNAH5 are always associated with predominantly static cilia whilst mutations
in different regions of DNAH11 can lead to either static cilia or hyper frequent, stiff cilia [45, 108].
Therefore, to confirm the genetic cause of PCD, the ultrastructural defect and gene should correlate; in the
future, we may be able to use gene mutation ciliary pattern correlations as further support.
In principle, all DNA sequencing technologies can be applied for genetic testing in patients with a confirmed
PCD or a high suspicion of PCD (see supplementary material). However, due to the high number and the huge
size of PCD genes high-throughput techniques are now widely used. The yield of allele-specific approaches is
low in PCD given the high genetic and allelic heterogeneity. Detected mutations should be confirmed by Sanger
sequencing and checked for segregation in the parents. Genetic laboratories have to be aware that large
heterozygous genomic deletions have been reported in PCD individuals that might be missed by DNA
sequencing technologies. Homozygous and heterozygous intragenic large duplications and deep intronic
mutations are also missed by sequencing techniques. The detection of intragenic deletions and duplications will
benefit from the fine set-up of targeted next generation sequencing panels; however, this approach requires
specific development and sensitivity assessment. All techniques, especially the second line approaches, benefit
from the knowledge of the ultrastructural defect of the patient in order to assess the relevance of the molecular
findings. The ≈30 PCD genes implicated to date encompass >700 exons and thus it is not unusual to identify a
heterozygous variant in a gene that is obviously not responsible for the disease of the patient based on
ultrastructural data. Cell and whole organism models can be used to confirm that a gene is disease causing.
Review of evidence directly addressing the question “in patients suspected of having PCD, should
genotyping be used as a diagnostic tool?”
Searches identified 462 studies, of which 95 met inclusion criteria for qualitative assessment (table S8).
Most studies included patients with confirmed PCD with the aim of identifying novel genes rather than
diagnostic cohorts. There were no studies that fulfilled the inclusion criteria for quantitative assessment.
Narrative review of additional evidence
In populations with confirmed or highly suspected PCD diagnosis, it is possible to identify genetic
causation in 50–75% of cases [109, 110]. The sensitivity of genetic testing as a first-line diagnostic test for
PCD is currently unknown but is likely to be low. With the identification of further PCD genes and
high-throughput sequencing technologies, PCD genetic testing as “stand alone” testing might be
considered in the future. Genotyping is useful in instances where confirmation of the diagnosis is difficult
by other approaches (e.g. DNAH11, CCNO, MCIDAS and RSPH genes mutations). The detection of
bi-allelic disease-causing mutations in autosomal recessive PCD or hemizygous mutations in X-linked
PCD is highly specific.
Most studies to identify novel PCD gene defects used ultrastructural defects detected by routine TEM as
the starting point for the genetics search; therefore, the likelihood to identify mutations in PCD with
ultrastructural defects is higher than in PCD devoid of ultrastructural defects. This underscores the need
not to rely on TEM as the sole diagnostic test for PCD.
Reports of mutations in specific genes typically relate to small numbers of patients and are not necessarily
ethnically representative; therefore, the contribution of each gene should be interpreted with caution.
Studies testing for DNAH5 and DNAI1 mutation suggest that these mutations account for ∼50–70% of
cases of ODA defects [94, 95, 111, 112]. Mutations in CCDC39 or CCDC40 [89, 90, 103, 113] account for
almost all PCD individuals with microtubular disorganisation and absence of IDA. Of 58 unrelated PCD
patients with normal ultrastructure, 22% had bi-allelic mutations in DNAH11 [96]. Mutations in the genes
encoding radial spoke head and stalk proteins (RSPH1, RSPH3, RSPH4A, RSPH9), HYDIN and nDRC
proteins (DRC1, CCDC65, GAS8) can cause PCD with normal or subtly abnormal ultrastructure (table 7);
to date, the contribution of these genes to the prevalence of PCD has not been determined.
A systematic population-based genetic Israeli study revealed that RGMC may be more frequent (6%) in
their particular PCD populations than previously estimated [106].
Genetic analyses have shown that mutations in the RGMC genes CCNO and MCIDAS, as well as the genes
encoding radial spoke proteins (RSPH1, RSPH3, RSPH4A, RSPH9) and the central pair associated protein
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HYDIN, do not result in laterality defects. In addition, to date all PCD individuals carrying bi-allelic
mutations in genes encoding nDRC proteins such as CCDC164, CCDC65 and GAS8 did not exhibit any
situs abnormalities.
Given the large size of the regions sequenced in PCD patients, it is not unusual to identify one or several
rare missense variants that are not linked to the disease. Great care should be taken to interpret those
variants. It is important to perform segregation analysis for those variants and their interpretation can rely
on expert labs. In some cases immunofluorescence microscopy has been proven to be a useful tool to
determine pathogenicity of missense mutations in PCD individuals with mutations in RSPH4A and
RSPH9 that encode radial spoke head proteins [86]. However, immunofluorescence analysis can be normal
if the mutated protein is still expressed and correctly assembled within the axonemes, such as reported for
DNAH11 missense mutations [97].
We did not find evidence to either confirm or refute genotyping as a diagnostic test for PCD. Whilst there
is a need for evidence of the utility of genotyping in a diagnostic setting, table 8 summarises the Task
Force assessment of currently published evidence in genetic testing in PCD.
Key unanswered questions and research needs
The role of genetic testing is not well defined in the PCD diagnostic pathway. We need studies to
investigate the accuracy and limitations of genetics as a diagnostic tool for PCD. The standards for
diagnostic testing for PCD need defining.
Summary
We were unable to determine the accuracy of genetic testing due to lack of suitable studies. Several studies
have identified the genes responsible in patients with confirmed PCD, suggesting that genetic testing
identifies the gene in ∼65% of cases; this is likely to increase as more genes are identified. The question of
diagnostic accuracy should be revisited as new data become available.
Immunofluorescence
In patients suspected of having PCD, should immunofluorescence be used as a diagnostic tool? There were
no studies that fulfilled inclusion criteria to answer this question.
Explanation of the diagnostic test
Labelling of ciliary proteins was developed to improve understanding of the impact of disease-causing
genes on ciliary proteins [116]. Specific antibodies with secondary fluorescent tags localise to proteins in
human respiratory epithelial cells and are visualised by fluorescent or confocal microscopy. A number of
antibodies against ciliary proteins are available, including antibodies targeting the ODA, IDA, radial spoke
head and dynein regulatory complex proteins. An example of this technique is shown in figure 3.
Respiratory epithelial cells in suspension are placed onto glass slides, air dried and fixed. The cells are
incubated with antibodies to ciliary protein not implicated in PCD (e.g. acetylated tubulin) to label the
axoneme and combined with antibodies of interest produced in a different species (e.g. anti-DNAH5 to
identify ODA structures).
TABLE 8 Summary of the Task Force consensus on the published evidence on genetic testing in primary ciliary dyskinesia
(PCD) diagnostics
Whilst further evidence in a diagnostic setting is required, experts of the Task Force agreed:
1. Genetic testing to confirm diagnosis can be performed in PCD individuals diagnosed by other means
(e.g. HSVA, TEM, IF) or in individuals with high clinical suspicion for PCD (typical clinical findings, low nNO) and no availability of other
investigations, such as HSVA, TEM or IF. A negative genetic test does not exclude PCD.
2. Genetic testing can also be performed to establish diagnosis in patients highly suspected of PCD and in whom HSVA, TEM or IF failed to
confirm the diagnosis, as can be the case for patients with DNAH11, CCNO, MCIDAS or RSPH gene mutations.
3. Genetic testing and interpretation of results should follow national and international best practice guidelines [114, 115].
4. Genetic diagnosis has to be consistent with the clinical and TEM/IF/HSVA phenotype, or diagnosis reconsidered if the picture is
inconsistent.
5. Allelic segregation analysis within the family (especially in both parents) is important to confirm the genotype in the probands (to
differentiate between homozygosity and hemizygosity, and between compound heterozygosity and a complex allele).
6. Genetic testing in probands and in their relatives is helpful for genetic counselling to inform reproductive choices.
7. In the future genetic testing might be important for genotype specific therapy.
HSVA: high-speed video microscopy analysis; TEM: transmission electron microscopy; IF: immunofluorescence; nNO: nasal nitric oxide.
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a)
b)
c)
DNAH5
acet. Tubulin
GAS8
CCDC39
Merge
Merge
DIC
DIC
acet. Tubulin RSPH9 Merge DIC
Control
GAS8 mutant
Control
Control
CCDC39 mutant
RSPH9 mutant
FIGURE 3 Immunofluorescence microscopy can be used to identify structural defects of motile cilia and to aid
diagnosis of primary ciliary dyskinesia. Three examples of abnormal staining are presented. a) Antibodies
directed against the outer dynein arm heavy chain DNAH5 (green) are used to detect the outer dynein arm
complex along the entire ciliary lengths within the control and a person carrying a GAS8 Mutation. The
antibodies directed against GAS8 (red) can identify isolated defects of the nexin-dynein regulatory complex. b)
Antibodies against CCDC39 (red) can detect defects of the 96-nm axonemal ruler, which consists of CCDC39
and CCDC40. Anti-acetylated tubulin (green) antibodies are used to depict the cilia. c) Antibodies against
RSPH9 (red) can be used to identify various defects of the radial spoke head complex. Normal localisation of
ciliary components is shown by co-localisation (yellow colour) with ciliary axonemal markers such as
acetylated tubulin (green in b and c) or unaffected ciliary components (i.e. DNAH5, green in a). In contrast,
absence of structural components involved in ciliary motility is shown by absence of the protein in mutant
cells (lower panels in a–c). Nuclei are shown in blue. DIC: differential interference contrast microscopy. Scale
bars=10 µm.
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Review of evidence directly addressing the question “in patients suspected of having PCD, should
immunofluorescence be used as a diagnostic tool?”
Our search identified 276 studies (figure S1). No studies reported use of immunofluorescence antibodies
in a diagnostic setting and we were, therefore, unable to establish the accuracy of IF as a diagnostic test. 40
studies contributed to our understanding of the potential to use immunofluorescence diagnostically, as
summarised below (table S9).
Narrative review of additional evidence
Although the literature focuses on research to understand the downstream effects of mutations in
PCD-related genes (table 7), several centres now use immunofluorescence to aid diagnosis [117]. This is
likely to increase as more antibodies become available, and once data for the accuracy of the tests becomes
available. In the two largest patient-based cohort studies, DNAH5 immunofluorescence was tested in 16
PCD patients and a further 17 families who had ODA defects observed by TEM; mislocalisation of the
protein was reported in all cases. Furthermore, DNAH5 protein was present in patients with cystic fibrosis
and in healthy controls [94, 95]. A number of studies have used immunofluorescence to examine protein
mislocalisation related to genetic mutations (table 7), providing indicators to the antibodies that might be
used and findings expected when immunofluorescence is used as a diagnostic test. Immunofluorescence
can identify mislocalisation of proteins in PCD patients with a range of mutations, providing information
on the pathogenicity of a mutation [86]. However, most manuscripts report immunofluorescence findings
from small numbers of patients for each gene and mutation specific findings are not yet known.
With immunofluorescence it is possible to identify almost all ultrastructural abnormalities detectable by
TEM and also some cases where the TEM is apparently normal or subtly abnormal [30, 86, 97]. The
sensitivity and specificity of immunofluorescence is unknown but will reflect the combination and quality of
antibodies. In the authors’ experience, a number of antibodies do not work and validation including
appropriate disease and healthy controls is required before they are used diagnostically. Immunofluorescence
analysis can be normal if the mutated protein is still expressed within the axoneme [97].
We did not find evidence to either confirm or refute immunofluorescence as a diagnostic test for PCD.
Whilst further evidence in a diagnostic setting is required, a summary of the Task Force findings from
published evidence are shown in table 9.
Key unanswered questions and research needs
We need validation studies to investigate the accuracy and limitations of immunofluorescence as a
diagnostic tool for PCD in diagnostic cohort studies. Each applied antibody needs validation in studies
including appropriate PCD disease and healthy controls.
Summary
We were unable to determine the accuracy of immunofluorescence testing due to lack of suitable studies.
Task force experts agree that immunofluorescence can be useful in clinical settings. Immunofluorescence is
cheaper and easier than other diagnostic tests, providing a potential test for resource-limited settings.
Confirming or excluding a diagnosis of PCD
The Delphi Consensus Survey comprised four consecutive online surveys, each building on former rounds.
The outcomes of each round are summarised in table S11. Experts from the ERS Task Force agreed (⩾80%
of respondents) on the following, which enabled us to propose a diagnostic algorithm (figure 4).
Positive diagnosis
For patients with a supportive history of PCD, the following results are confirmatory of a positive
diagnosis of PCD.
1) Hallmark ciliary ultrastructure defects for PCD (absence of ODA, combined absence of IDA and ODA,
IDA absence combined with microtubular disarrangement) assessed by TEM.
2) Non-ambiguous bi-allelic mutations in PCD causing genes.
The Task Force did not reach consensus (80%) that any other test in isolation or in combination could
provide a conclusive positive diagnosis.
Highly likely diagnosis
In patients with a compatible history of PCD, the following diagnostic test results make the diagnosis of
PCD highly likely, but do not provide a definitive PCD diagnosis.
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1) Very low nNO plus HSVA findings consistently suggestive of PCD (e.g. static cilia or circling) on three
occasions.
2) Very low nNO plus HSVA findings consistent with PCD (e.g. static cilia or circling) following cell culture.
If the diagnosis is “highly likely” but not conclusive, patients should be told that the diagnosis is likely but
given the limitations of diagnostic tests, the diagnosis is not 100% certain and might need confirmation when
better tests become available. Patients should have other causes for their symptoms excluded and should be
treated as if they have PCD. As new diagnostic tests become available further investigations should be offered.
Excluding the diagnosis of PCD
The Task Force did not reach consensus (80%) that any single test or combination of tests could exclude a
diagnosis of PCD. However, based on the evidence reviewed they agreed that there are conditions under
which the diagnosis is “extremely unlikely”. If the clinical suspicion is only modest and nNO is high/
normal plus normal HSVA or nNO is high/normal plus normal HSVA following cell culture.
The patient can be counselled that the diagnosis is extremely unlikely and that further testing is not
warranted. If the clinical suspicion is very high (e.g. Kartagener’s syndrome, PICADAR score ⩾10) current
diagnostic tests are not sufficiently accurate to exclude a diagnosis.
General statements
Members of the Task Force suggest that diagnostic tests should only be conducted in laboratories with
expertise in the field. The results should be interpreted by specialists with expertise in PCD and the results
explained to the patient and their non-specialist carers. Diagnostic tests for PCD are currently imperfect.
As our understanding and techniques for PCD advance, patients with a high clinical suspicion or
inconclusive test results can be recalled and offered repeat testing.
A number of patients have diagnostic tests which do not satisfy the criteria for being labelled positive,
highly likely or extremely unlikely. These patients should be considered inconclusive; further investigation
and management should be determined by a specialist with expertise in PCD.
Diagnostic algorithm
Based on the culmination of evidence from the GRADE recommendations and the Delphi Consensus
statement, the following step-wise approach to diagnostic testing can be used (figure 4). Not all patients
need to undergo all steps. For many patients, step 1 (nNO and HSVA) will provide a “highly unlikely”
diagnosis, and patients won’t need further investigations. Some patients should proceed to step 2 (TEM or
cell culture with repeat HSVA). Genetics testing (step 3) may help make a diagnosis in patients where
other tests have failed to provide a definitive diagnostic outcome. Patients who remain “inconclusive”
could be recalled in the future as further tests become available. This approach will not be appropriate for
all diagnostic services; local expertise and equipment should be taken into consideration.
Step 1: nNO and HSVA
If both are entirely normal, the diagnosis of PCD is very unlikely and further testing can be avoided unless
the clinical suspicion is particularly high. If nNO is low and/or HSVA is abnormal PCD is the likely/
possible diagnosis. Repeat the step 1 tests and proceed to step 2.
Step 2: TEM
If TEM is normal consider genetics testing for genes associated with normal or subtle TEM defects and
repeat HSVA following cell culture. If TEM shows “hallmark” defects PCD is confirmed, consider genetics
testing to further characterise the underlying defect.
TABLE 9 Summary of the Task Force consensus on the published evidence on
immunofluorescence testing in primary ciliary dyskinesia (PCD) diagnostics
Whilst further evidence in a diagnostic setting is required, experts of the Task Force agreed:
1. Immunofluorescence is able to confirm pathogenesis of mutations (e.g. missense mutations in genes
encoding radial spoke proteins)
2. Immunofluorescence can detect PCD in some cases with normal ultrastructure or subtle
ultrastructural defects
3. Immunofluorescence can help establish the diagnosis of PCD in outer and inner dynein arms, tubular
disorganisation (CCDC39/CCDC40 mutations), central pair (genes encoding radial spoke proteins) and
nexin link defects
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Step 3: Genetics and repeat HSVA ± cell culture.
Further testing
In patients where the diagnosis is highly likely or remains inconclusive, further investigations such as
immunofluorescence or radio-aerosol mucociliary clearance analysis might be used but the evidence is too
limited for us to recommend them. PCD clinicians should consider recalling these patients for further
testing in the future, as advances in PCD diagnostics are made.
Discussion
The ERS Task Force presents the first evidence-based guideline for the diagnosis of PCD. This is timely, as
new diagnostic tests (e.g. ciliary protein immunofluorescence and genetic testing) are increasingly
introduced along with refinement of existing tests (e.g. electron microscopy tomography and computational
averaging). As new evidence arises, the guidelines will need revisiting. We have provided guidance on who
should be referred for diagnostic testing. We have confirmed that no diagnostic test is perfect, and in the
absence of a gold standard, access to a combination of tests is necessary. Using a modified Delphi approach
we then used the evidence for individual tests to develop a diagnostic algorithm, providing the criteria to
define patients as positive, highly unlikely, extremely unlikely and inconclusive.
The studies that contribute to the recommendations were all conducted in specialist PCD diagnostic
centres. The tests are generally complex, requiring experienced scientists and clinicians to analyses and
interpret results. Therefore, our findings provide evidence for diagnostic centres with high throughput of
samples, analysed by experienced technicians and with good quality control. New diagnostic centres will
require support from experienced centres for training and ongoing quality control/assessment. BEATPCD
(COST ACTION BM 1407; www.beatpcd.org/) is coordinating a programme of research and training to
improve the diagnosis and treatment of PCD. This includes provision of training schools, bursaries for
short-term placements in specialist centres and networking for discussion of difficult and equivocal
diagnostic decisions. Together with the anticipated European Reference Network for PCD, the
collaborative approach should drive up standards of diagnostic testing across Europe.
Clinical history
STEP 1
nNO and HSVA
PCD
highly unlikely
Tests normal and
history not strong
HSVA suggestive of PCD 
on three separate 
occasions and nNO lowFurther tests unlikely
to be needed Consider STEP 3
Consider STEP 3
PCD
highly likely
PCD
highly likely
PCD positive
PCD positive
STEP 2
TEM and cell culture
± repeat HSVA
STEP 3
Genetic testing
Pathogenic 
bi-allelic mutations
Tests normal or equivocal;
or history very strong
TEM normal, nNO normal and 
HSVA normal following cell 
culture; history not strong
History very strong or test 
results abnormal/equivocal
Proceed to STEP 2
Hallmark TEM defect
nNO low and HSVA 
suggestive of PCD 
following cell culture,
with normal TEM
Consider additional investigations, 
such as radioaerosol mucociliary clearance
Recall patient for further testing in the future 
when new tests become available
Tests normal or equivocal;
or history very strong consider
STEP 3
FIGURE 4 Following development of recommendations using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation)
approach, a Delphi survey allowed us to propose a diagnostic algorithm for primary ciliary dyskinesia (PCD). Not all patients need to go through all
steps. Please see the text for details of the implications of each diagnostic outcome (positive, highly likely and highly unlikely), as well as the
consequences for patients who will continue to have an inconclusive outcome using currently available diagnostic tests. Patients with uncertain
outcomes should be reconsidered for further testing as advances in diagnostic tests are made. nNO: nasal nitric oxide; TEM: transmission electron
microscopy; HSVA: high-speed video microscopy analysis.
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Results from diagnostic studies are an indirect measure of the downstream consequences of the application
of a test, and therefore the confidence in the test accuracy measures was judged, at best, as moderate to
low. Evidence from patients does not alter the strength of published evidence but was considered when
deciding the strength of recommendations. The Task Force conducted a questionnaire survey of 352 PCD
patients from 25 countries, and 20 in-depth interviews [7]. Patients told us that an accurate diagnosis was
an important outcome, leading to a better recognition of their problems by physicians and access to
effective treatment, thus improving their health and quality of life.
Once the Task Force recommendations were agreed, a modified Delphi survey was used to develop a
consensus on diagnostic approach. Experts from the Task Force agreed that results from TEM and genetic
testing can lead to a definite positive diagnosis. This provides a guide for future clinical trials as well as
clinical care, with the caution that our definition will systematically exclude PCD patients with normal
ciliary ultrastructure where the genetic mutations are not yet known. Furthermore, most of the Task Force
(>50%) considered that the following combinations of tests could lead to a positive diagnosis, but we did
not reach consensus (defined by ⩾80%): very low nNO plus hallmark HSVA consistently on two occasions
and very low nNO plus hallmark HSVA following cell culture (table S11). We have also defined conditions
where the diagnosis of PCD can be considered as “extremely likely” and where diagnosis is “extremely
unlikely”. Given the current evidence, it is not possible to exclude a diagnosis with 100% confidence, but
we have defined situations where further testing can reasonably stop. We anticipate that as our
understanding of PCD grows, new phenotypes for this highly heterogeneous condition will be described
that might not be detected by current diagnostic tests.
All studies that contribute to our recommendations were hampered by the lack of a gold standard to
investigate the accuracy of individual tests. We therefore accepted manuscripts that constructed a reference
standard from a number of tests (composite diagnostic outcome) or used an imperfect test, e.g. TEM as a
surrogate [118]. Studies using TEM or genetics as the reference standard will systematically exclude PCD
patients with normal ultrastructure or where the genetic mutation is not known. Additionally, some of the
evidence was based on studies where the index test was included in the composite diagnostic decision.
These important limitations present a strong risk of bias and may have over inflated or deflated the
sensitivity and specificity that we report for each test. None of the diagnostic tests had internationally
agreed standards for conduct or reporting. This resulted in disparity of methods between the studies that
we reviewed. The Task Force suggests that the following need to be taken into consideration in order to
advance our understanding of diagnostic tests for PCD.
1) Methodologists should be involved in the design of future studies to investigate diagnostic accuracy of
tests. Consideration is needed for the lack of a perfect reference standard.
2) To allow comparisons between studies, international standards for conduct of diagnostic tests and
reporting of results is needed. The standards should be evidence based.
3) Reporting of the clinical phenotype of patients included in diagnostic studies should be improved and
standardised.
4) Impact of a diagnosis on patient outcome and quality of life should be investigated.
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